Patents by Inventor Paul W. Kincade

Paul W. Kincade has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7592003
    Abstract: The discovery of Toll-like receptors (TLRs) on the surface of hematopoietic cells provides new methods for the stimulation and differentiation of various classes of progenitor cells. TLR2 and TLR4 agonists (natural ligands, mimetics, antibodies) are particularly useful in these methods. The cells can be isolated and used for various purpose including tissue regeneration and grafting. In contrast, antagonists of TLRs can be used to protect cells from various insults such as chemo- and radiotherapy, acute and chronic infection, and transplantation by inhibiting activation and differentiation. TLR2, TLR4 and TLR9 pathway antagonists (soluble TLR, mimetics, antibodies) are particularly useful in these methods. Cells can be isolated and used for various purposes including transplantation.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: September 22, 2009
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Yoshinori Nagai, Paul W. Kincade
  • Publication number: 20030104569
    Abstract: A novel protein having the activity to suppress proliferation of lympho-hematopoietic cells derived from BNS2.4 cells, its gene, a method for preparing them and their uses are provided. The novel protein has been identified from a stromal cell line BMS2.4 by expression cloning targeting mouse myelomonocytic leukemia cell line WEHI3. This protein and its gene are useful for treating lympho-hematopoietic disorders.
    Type: Application
    Filed: November 14, 2002
    Publication date: June 5, 2003
    Inventors: Kenji Oritani, Yoshiaki Tomiyama, Yuji Matsuzawa, Paul W. Kincade
  • Patent number: 6518043
    Abstract: A novel protein having the activity to suppress proliferation of lympho-hematopoietic cells derived from BNS2.4 cells, its gene, a method for preparing them and their uses are provided. The novel protein has been identified from a stromal cell line BMS2.4 by expression cloning targeting mouse myelomonocytic leukemia cell line WEHI3. This protein and its gene are useful for treating lympho-hematopoietic disorders.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: February 11, 2003
    Assignees: Oklahoma Medical Research Foundation, Center for Advanced Science and Technology Incubation, Ltd.
    Inventors: Kenji Oritani, Yoshiaki Tomiyama, Yuji Matsuzawa, Paul W. Kincade
  • Publication number: 20020132773
    Abstract: The stromal cells that support blood cell production within bone marrow are pre-adipocytes and functional interactions with marrow fat cells have long been suspected. Adiponectin was recently isolated as an adipocyte product and shown to have structural similarities to Clq as well as members of the TNF superfamily. It suppresses myeloid differentiation in short term bone marrow cultures and also inhibits macrophage functions. These observations raised the possibility that precursors of other blood cell lineages interact with fat cells in marrow via adiponectin. It has now been determined that the factor blocks B lymphopoiesis in Whitlock-Witte type bone marrow cultures, but not the production of myeloid cells in Dexter cultures. Several observations suggest that non-lymphoid cells represent the target of this new mediator, and the B lymphoid lineage is only indirectly influenced. Highly purified lymphocyte precursors in stromal cell-free, serum-free cultures were unaffected by adiponectin.
    Type: Application
    Filed: March 14, 2002
    Publication date: September 19, 2002
    Applicant: Oklahoma Medical Research Foundation
    Inventors: Paul W. Kincade, Takafumi Yokuta
  • Patent number: 5554595
    Abstract: Based on the discovery that normal pregnant mice have a striking reduction in committed precursors of B lymphocytes, which could be documented in mice as early as day 6 of gestation, when IL-7 responding colony forming cells were reduced as much as two-thirds of normal levels, it has been determined that estrogen and other hormones elevated in pregnancy induce a specific modulation of lymphocyte formation during pregnancy and lactation. It is therefore possible to immunomodulate in a specific manner an animal by administration of hormones elevated during pregnancy, such as estrogen and estrogen-like compounds, or antagonists of estrogen. This has potential in the treatment of a number of disorders, especially those found in very high percentages of women as compared with men, such as many of the autoimmune disorders, as well as in immune tolerance during pregnancy, cyclic neutropenia, and osteoporosis.
    Type: Grant
    Filed: October 11, 1994
    Date of Patent: September 10, 1996
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Paul W. Kincade, Kay L. Medina
  • Patent number: 5494899
    Abstract: It has been determined that estrogen and other hormones elevated in pregnancy induce a specific modulation of lymphocyte precursor cell production. The immune system of an animal or bone marrow cells in culture can therefore be modulated in a specific manner by administration of hormones elevated during pregnancy, such as estrogen and estrogen-like compounds or compounds that interfere with the synthesis or activity of these hormones, to increase or decrease production of B lymphocyte precursor cells.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: February 27, 1996
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Paul W. Kincade, Kay Medina